Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?

Evans, D Gareth R; Howell, Sacha J; Howell, Anthony

dc.contributor.author	Evans, D Gareth R
dc.contributor.author	Howell, Sacha J
dc.contributor.author	Howell, Anthony
dc.date.accessioned	2019-10-04T09:48:26Z
dc.date.available	2019-10-04T09:48:26Z
dc.date.issued	2019	en
dc.identifier.citation	Evans DG, Howell SJ, Howell A. Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy? Fam Cancer. 2019 Aug 23.	en
dc.identifier.pmid	31444676	en
dc.identifier.doi	10.1007/s10689-019-00142-8	en
dc.identifier.uri	http://hdl.handle.net/10541/622119
dc.language.iso	en	en
dc.relation.url	https://dx.doi.org/10.1007/s10689-019-00142-8	en
dc.title	Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?	en
dc.type	Article	en
dc.contributor.department	NW Genomic Laboratory hub, Manchester Centre for Genomic Medicine, Manchester University Hospitals NHS Foundation Trust, Manchester, M13 9WL	en
dc.identifier.journal	Familial Cancer	en
dc.description.note		en]
refterms.dateFOA	2019-10-06T20:28:44Z